Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 171 publications
Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study.
Journal: Focus (American Psychiatric Publishing)
Published: August 01, 2026
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial.
Journal: The Journal of clinical psychiatry
Published: May 07, 2026
NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: April 02, 2026
The Randomization Effect in a Double-Blind Placebo-Controlled Depression Study.
Journal: Journal of clinical psychopharmacology
Published: March 31, 2026
The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus.
Journal: The British journal of psychiatry : the journal of mental science
Published: March 25, 2026
Comment on Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions.
Journal: The American journal of psychiatry
Published: March 18, 2026
Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force.
Journal: JAMA network open
Published: February 25, 2026
Evaluating a New Addition to the Treatment Toolbox for Major Depressive Disorder.
Journal: The American journal of psychiatry
Published: December 01, 2025
Transdiagnostic connectome-based predictive modeling of many behavioral phenotypes reveals brain network mediators of clinical-cognitive relationships.
Journal: bioRxiv : the preprint server for biology
Published: November 19, 2025
Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.
Journal: Neurologic clinics
Published: November 13, 2025
Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression.
Journal: Journal of clinical psychopharmacology
Published: October 13, 2025
Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.
Journal: Contemporary clinical trials
Published: October 02, 2025
Last Updated: 09/26/2026